Hologic Inc. (HOLX)

Name: Hologic Inc. (HOLX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Hologic Inc. (HOLX)

Stock Card

$76.01

$0.00 (0.00%)

As on 07-Apr-2026 09:30EDT

Market cap

$16,969 Mln

Revenue (TTM)

$4,126 Mln

P/E Ratio

31.5

P/B Ratio

3.2

Div. Yield

0 %

Hologic (HOLX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 76.01 High: 76.01

52 Week Range

Low: 51.90 High: 76.04

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

0.1 %
ROCE

7.3 %
Industry P/E

44.46
EV/EBITDA

16
Debt to Equity

0.5
Book Value

$--
EPS

$2.4
Face value

--
Shares outstanding

223,244,905

10 Years Aggregate

CFO

$9,876.30 Mln

EBITDA

$12,722.00 Mln

Net Profit

$5,828.40 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Hologic (HOLX)	2.0	0.4	1.5	24.9	-2.8	0.3	7.8
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P 100^#	10.3	5.0	2.3	18.8	22.8	13.0	14.8

As on 07-Apr-2026 | *As on 28-Aug-2026 | #As on 28-Aug-2026

Company	2025	2024	2023	2022	2021	2020	2019
Hologic (HOLX)	3.3	0.9	-4.5	-2.3	5.1	39.5	27.0
S&P 100	18.7	29.0	30.8	-22.1	27.6	19.3	29.5
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Hologic (HOLX)

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments:... Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts. Read more

Chairman, CEO & President

Mr. Stephen P. MacMillan
Chairman, CEO & President

Mr. Stephen P. MacMillan
Headquarters

Marlborough, MA
Website

https://www.hologic.com

FAQs for Hologic (HOLX)

What is the current share price of Hologic Inc (HOLX) Today?

The share price of Hologic Inc (HOLX) is $76.01 (NASDAQ) as of 07-Apr-2026 09:30 EDT. Hologic Inc (HOLX) has given a return of -2.84% in the last 3 years.

What is the current PB & PE ratio of Hologic Inc (HOLX)?

The P/E ratio of Hologic Inc (HOLX) is 31.54 times as on 07-Apr-2026, a 29 discount to its peers’ median range of 44.46 times.
The P/B ratio of Hologic Inc (HOLX) is 3.24 times as on 07-Apr-2026, a 16 discount to its peers’ median range of 3.84 times.

PE & PB ratio at the end of financial year.